Glow peptide studies and regulatory sources

Clinical assessments of the three ingredients

Mendias and Awan’s 2026 Sports Medicine review is the broad assessment here: favorable animal repair findings, scarce rigorous human safety evidence and potential for harm. McGuire and colleagues’ 2025 BPC-157 review examines the small human pilots and treats the substance as investigational. For me, those assessments deserve as much room as the appealing results from the early experiments.

The skin shelf

The 2015 skin-regeneration review and the 2008 tissue-remodeling review are the main GHK-Cu sources. The 2018 gene-data review adds cell and database work; the 2016 hair trial tests a GHK-containing topical complex with another ingredient. That last distinction is why the hair result cannot be filed as a GLOW trial.

Tendon, wound and protein

The cut rat Achilles-tendon study and the VEGFR2 study concern BPC-157. The rat wound paper, the regenerative review and the actin-binding structural study concern thymosin beta-4. The healthy-volunteer safety study also used the full-length protein. I prefer those names to stay visible; the parent protein and TB-500 require separate evidence.

The FDA shelf has dates attached

The Section 503A framework, the safety-risk and withdrawn-nominations page, the advisory-meeting page, the interim policy and the cosmetics page support the regulatory discussion. The audited link-check date, 2026-05-29, marks link verification alone; publication and FDA-action dates are separate.

The meeting page records an agenda; the outcome of an agency decision remains undocumented here. The legal-status page states what this source record can establish. Below is the full audited list, including the formal titles and identifiers.